Pulse nav.journalClub 活発な議論トレンド探索質問研究者

Download the App

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

© Synapse Social LLC, 2026

プライバシーポリシー

ホーム探索 nav.journalClub トレンド

⌘+K

Human macrophage-engineered vesicles for utilization in ovarian cancer treatment | Synapse

January 11, 2023Open Access

Human macrophage-engineered vesicles for utilization in ovarian cancer treatment

Key Points

Key points are not available for this paper at this time.

Abstract

Human M1 MEVs can repolarize M2 macrophages to a M1 state and have anti-cancer activity against ovarian cancer cell lines. RAW264.7 M1 MEVs localize to tumor xenografts in vivo murine models.

Like

Bookmark

Share

View Full Paper

Like

Bookmark

Share

View Full Paper

Cite This Study

Schweer et al. (Wed,) studied this question.

synapsesocial.com/papers/69d707e9a0177bf533ed992a https://doi.org/https://doi.org/10.3389/fonc.2022.1042730

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Recurrent ovarian cancer2016 · 49 citations
2Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges2016 · 1,338 citations
3Exosomes in cancer development, metastasis, and immunity2019 · 991 citations
4Ovarian Cancer Cells Polarize Macrophages Toward A Tumor-Associated Phenotype2006 · 408 citations
5Murlentamab, a Low Fucosylated Anti-Müllerian Hormone Type II Receptor (AMHRII) Antibody, Exhibits Anti-Tumor Activity through Tumor-Associated Macrophage Reprogrammation and T Cell Activation2021 · 9 citations